BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 12187169)

  • 1. Utility of the SEER-Medicare data to identify chemotherapy use.
    Warren JL; Harlan LC; Fahey A; Virnig BA; Freeman JL; Klabunde CN; Cooper GS; Knopf KB
    Med Care; 2002 Aug; 40(8 Suppl):IV-55-61. PubMed ID: 12187169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying specific chemotherapeutic agents in Medicare data: a validation study.
    Lund JL; Stürmer T; Harlan LC; Sanoff HK; Sandler RS; Brookhart MA; Warren JL
    Med Care; 2013 May; 51(5):e27-34. PubMed ID: 22080337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studying radiation therapy using SEER-Medicare-linked data.
    Virnig BA; Warren JL; Cooper GS; Klabunde CN; Schussler N; Freeman J
    Med Care; 2002 Aug; 40(8 Suppl):IV-49-54. PubMed ID: 12187168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of SEER Treatment Data With Medicare Claims.
    Noone AM; Lund JL; Mariotto A; Cronin K; McNeel T; Deapen D; Warren JL
    Med Care; 2016 Sep; 54(9):e55-64. PubMed ID: 24638121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.
    Chawla N; Yabroff KR; Mariotto A; McNeel TS; Schrag D; Warren JL
    Ann Epidemiol; 2014 Sep; 24(9):666-72, 672.e1-2. PubMed ID: 25066409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study.
    Fleming ST; Kimmick GG; Sabatino SA; Cress RD; Wu XC; Trentham-Dietz A; Huang B; Hwang W; Liff JM;
    Ann Epidemiol; 2012 Nov; 22(11):807-13. PubMed ID: 22948184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Completeness of Managed Care Data to Identify Cancer Diagnoses and Treatments for Patients in the SEER-Medicare Data.
    Warren JL; Parsons HM; Mariotto AB; Boyd E; Enewold L
    Med Care; 2023 Dec; 61(12):846-857. PubMed ID: 37796197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of SEER-Medicare data for measuring cancer surgery.
    Cooper GS; Virnig B; Klabunde CN; Schussler N; Freeman J; Warren JL
    Med Care; 2002 Aug; 40(8 Suppl):IV-43-8. PubMed ID: 12187167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring complications of cancer treatment using the SEER-Medicare data.
    Potosky AL; Warren JL; Riedel ER; Klabunde CN; Earle CC; Begg CB
    Med Care; 2002 Aug; 40(8 Suppl):IV-62-8. PubMed ID: 12187170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER-Medicare Database.
    Lin CC; Virgo KS; Robbins AS; Jemal A; Ward EM
    Ann Surg Oncol; 2016 Dec; 23(13):4139-4148. PubMed ID: 27535406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment.
    Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA
    Med Care; 2000 Apr; 38(4):411-21. PubMed ID: 10752973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of three algorithms to identify incident breast cancer in Medicare claims data.
    Gold HT; Do HT
    Health Serv Res; 2007 Oct; 42(5):2056-69. PubMed ID: 17850533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy and completeness of Medicare claims data for surgical treatment of breast cancer.
    Du X; Freeman JL; Warren JL; Nattinger AB; Zhang D; Goodwin JS
    Med Care; 2000 Jul; 38(7):719-27. PubMed ID: 10901355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.
    Klabunde CN; Legler JM; Warren JL; Baldwin LM; Schrag D
    Ann Epidemiol; 2007 Aug; 17(8):584-90. PubMed ID: 17531502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of Medicare claims data for measuring cancer stage.
    Cooper GS; Yuan Z; Stange KC; Amini SB; Dennis LK; Rimm AA
    Med Care; 1999 Jul; 37(7):706-11. PubMed ID: 10424641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data.
    Huepenbecker SP; Zhao H; Sun CC; Fu S; He W; Giordano SH; Meyer LA
    JCO Clin Cancer Inform; 2022 Mar; 6():e2100187. PubMed ID: 35297648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of electronic data on chemotherapy and hormone therapy use in HMOs.
    Ritzwoller DP; Carroll N; Delate T; O'Keeffe-Rossetti M; Fishman PA; Loggers ET; Aiello Bowles EJ; Elston-Lafata J; Hornbrook MC
    Med Care; 2013 Oct; 51(10):e67-73. PubMed ID: 22531648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data sources for measuring colorectal endoscopy use among Medicare enrollees.
    Schenck AP; Klabunde CN; Warren JL; Peacock S; Davis WW; Hawley ST; Pignone M; Ransohoff DF
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2118-27. PubMed ID: 17932360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis date agreement between SEER and Medicare claims data: impact on treatment.
    Lin CC; Virgo KS
    Med Care; 2014 Jan; 52(1):32-7. PubMed ID: 24322987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construct validity of medicare chemotherapy claims: the case of 5FU.
    Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA
    Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.